Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HOOK 
Hookipa Pharma Inc (HOOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: HOOK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -11.49% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.42M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 56738 | Beta 0.7 | 52 Weeks Range 0.88 - 10.50 | Updated Date 04/1/2025 |
52 Weeks Range 0.88 - 10.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-20 | When Before Market | Estimate -0.69 | Actual -0.74 |
Profitability
Profit Margin -98.99% | Operating Margin (TTM) -1267.65% |
Management Effectiveness
Return on Assets (TTM) -22.96% | Return on Equity (TTM) -61.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -25889428 | Price to Sales(TTM) 0.33 |
Enterprise Value -25889428 | Price to Sales(TTM) 0.33 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 9659520 | Shares Floating 9536526 |
Shares Outstanding 9659520 | Shares Floating 9536526 | ||
Percent Insiders 2 | Percent Institutions 58.65 |
Analyst Ratings
Rating 3.75 | Target Price 16.33 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hookipa Pharma Inc
Company Overview
History and Background
Hookipa Pharma Inc. was founded in 2011. It is a biopharmaceutical company focused on developing immunotherapies based on its proprietary arenavirus platform.
Core Business Areas
- Oncolytic Virus Therapy: Develops oncolytic viruses designed to directly kill cancer cells and stimulate an immune response against the tumor.
- Prophylactic Vaccines: Focuses on prophylactic vaccines designed to prevent infectious diseases.
Leadership and Structure
The company's leadership includes key executives in research and development, clinical operations, and finance. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical trials, manufacturing, and commercialization (if applicable).
Top Products and Market Share
Key Offerings
- HB-101: An arenaviral immunotherapy targeting cytomegalovirus (CMV). Currently in clinical development. Market share data is not yet applicable as it is pre-commercialization. Competitors include companies developing CMV vaccines, such as Moderna and Pfizer.
- HB-200 series: A series of arenaviral immunotherapies targeting cancers expressing the PRAME antigen. Currently in clinical development. Market share data is not yet applicable as it is pre-commercialization. Competitors include companies developing PRAME-targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for unmet medical needs.
Positioning
Hookipa Pharma Inc is positioned as a developer of novel immunotherapies based on its arenavirus platform. Its competitive advantages lie in its unique platform technology and potential to address difficult-to-treat diseases.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies and prophylactic vaccines is substantial, estimated to be in the tens of billions of dollars annually. Hookipa is positioned to capture a share of this market by developing effective treatments in its target areas.
Upturn SWOT Analysis
Strengths
- Proprietary arenavirus platform
- Novel immunotherapy approach
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Pre-commercial stage
- High risk of clinical trial failure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of platform technology to new indications
- Increased demand for immunotherapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BNTX
Competitive Landscape
Hookipa Pharma Inc faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and partnerships.
Future Projections: Future growth depends on the success of ongoing clinical trials and the ability to secure partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for HB-101 and HB-200 series and exploring new indications for its arenavirus platform.
Summary
Hookipa Pharma is a pre-commercial stage biotech focused on arenaviral immunotherapies. Its strength is in its novel platform, but weaknesses exist in its limited resources and reliance on clinical success. Success hinges on positive trial outcomes, strategic partnerships, and managing significant competition. The future growth trajectory depends on its ability to bring therapies to market and expand its platform application.
Similar Companies
BNTX
BioNTech SE
BNTX
BioNTech SE
MRNA
Moderna Inc
MRNA
Moderna Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hookipa Pharma Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-04-18 | CEO & Director Dr. Malte Peters M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 82 | Website https://www.hookipapharma.com |
Full time employees 82 | Website https://www.hookipapharma.com | ||
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.